What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Radiation therapy
Michael Bamberg spends much of his time researching Surgery, Radiation therapy, Chemotherapy, Internal medicine and Pathology.
Surgery and Clinical trial are frequently intertwined in his study.
His Radiation therapy research incorporates themes from Survival analysis, Nuclear medicine and Glioma.
Michael Bamberg has included themes like Concomitant, Primary tumor and Neuroectodermal tumor in his Chemotherapy study.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Oncology.
His research in Pathology intersects with topics in Progenitor cell, Receptor, Cytokine and Cell biology.
His most cited work include:
- NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide (641 citations)
- European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. (490 citations)
- High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial (392 citations)
What are the main themes of his work throughout his whole career to date?
Michael Bamberg mostly deals with Radiation therapy, Surgery, Internal medicine, Oncology and Chemotherapy.
Michael Bamberg has researched Radiation therapy in several fields, including Stage, Nuclear medicine and Pathology.
His work is dedicated to discovering how Pathology, Cancer research are connected with Apoptosis and other disciplines.
His study in the field of Survival rate, Retrospective cohort study, Regimen and Seminoma also crosses realms of Standard treatment.
As part of his studies on Internal medicine, Michael Bamberg often connects relevant areas like Gastroenterology.
His studies in Chemotherapy integrate themes in fields like Concomitant, Primary tumor and Glioma.
He most often published in these fields:
- Radiation therapy (44.11%)
- Surgery (32.55%)
- Internal medicine (30.19%)
What were the highlights of his more recent work (between 2009-2020)?
- Radiation therapy (44.11%)
- Internal medicine (30.19%)
- Oncology (22.91%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Radiation therapy, Internal medicine, Oncology, Surgery and Chemotherapy.
His work carried out in the field of Radiation therapy brings together such families of science as Prostatectomy, Survival analysis, Retrospective cohort study and Intensive care medicine.
His work deals with themes such as Follicular lymphoma, Prostate cancer, Toxicity and Temozolomide, which intersect with Oncology.
His studies in Surgery integrate themes in fields like Hyperthermia and Radiology.
His Chemotherapy research includes themes of Concomitant, Clinical endpoint and Methotrexate.
His Survival rate research is multidisciplinary, incorporating elements of Progressive disease, Combined Modality Therapy and Chemoradiotherapy.
Between 2009 and 2020, his most popular works were:
- High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial (392 citations)
- Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide (114 citations)
- Phase II Trial of a Trimodality Regimen for Stage III Non–Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study (62 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Radiation therapy
Radiation therapy, Surgery, Internal medicine, Chemotherapy and Oncology are his primary areas of study.
The study incorporates disciplines such as Prostate-specific antigen, Prostatectomy, Prostate cancer, Retrospective cohort study and Survival analysis in addition to Radiation therapy.
His Surgery study integrates concerns from other disciplines, such as Neoadjuvant therapy, Radiology and Fibrosis.
His Chemotherapy research incorporates themes from Concomitant, Methotrexate, Whole brain radiotherapy and Confidence interval.
His biological study spans a wide range of topics, including Mastectomy and Toxicity.
He has researched Chemotherapy regimen in several fields, including Primary central nervous system lymphoma, Progression-free survival, Glioma, Pathology and Ifosfamide.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
